Retatrutide

Retatrutide (LY3437943) is a groundbreaking triple agonist peptide that simultaneously activates three key metabolic receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR). This tri-agonist approach represents a new frontier in metabolic research, with the glucagon receptor component adding thermogenic and lipolytic effects to the incretin-mediated appetite suppression and insulin sensitization. Phase II clinical data demonstrated unprecedented weight loss results, with participants achieving up to 24% body weight reduction over 48 weeks. Research applications include studying the synergistic effects of multi-receptor agonism on glucose homeostasis, appetite regulation, energy expenditure, hepatic lipid metabolism, and cardiovascular risk factors. The glucagon component has been specifically studied for its effects on hepatic fat reduction and increased energy expenditure through BAT activation and futile cycling.